Literature DB >> 32267612

Genetic mosaicism in haemophilia: A practical review to help evaluate the risk of transmitting the disease.

Nathalie Lannoy1, Cedric Hermans1.   

Abstract

Approximately 70% of patients with haemophilia exhibit a clear inheritance pattern, while for the remaining 30%, patients are the first to be diagnosed in their family and are considered sporadic cases. In such a setting, the determination of carrier status and the risk estimation of disease transmission to another child are major challenges for genetic counselling. Large studies have suggested that genetic testing reveals 70% of sporadic patients' mothers are carriers. In the remaining 30%, in some apparently non-carrier mothers, the pathogenic variant can be detected as low somatic and gonosomal mosaicism. The significance of mosaic pathogenic variants has thus far been underestimated, since conventional Sanger sequencing and other technology are not sufficiently sensitive. The study of various tissue samples and recent extra-sensitive molecular methods have now made it easier to detect both single-nucleotide variants (SNVs) and copy-number variants (CNVs), at a mosaic level in parents, and to predict the probability of disease recurrence. This review seeks to examine various kinds of mosaicism in haemophilia, including the mechanisms by which they arise and the risk of passing these variants on to the next generation. In addition, we focus on the selection of cell tissues and methods to detect these mosaic variants in the haemophilia setting. Taking into account the high rate of mosaicism in mothers of sporadic cases, we propose a diagnostic flow chart that could facilitate better evaluation of the risk of transmitting haemophilia in genetic and prenatal counselling.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  F8 gene; F9 gene; germline mosaicism; gonosomal mosaicism; haemophilia A; haemophilia B; somatic mosaicism

Mesh:

Year:  2020        PMID: 32267612     DOI: 10.1111/hae.13975

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

Authors:  Ionut Hotea; Melen Brinza; Cristina Blag; Alina-Andreea Zimta; Noemi Dirzu; Corina Burzo; Ioana Rus; Dragos Apostu; Horea Benea; Mirela Marian; Alexandru Mester; Sergiu Pasca; Sabina Iluta; Patric Teodorescu; Ciprian Jitaru; Mihnea Zdrenghea; Anca Bojan; Tunde Torok-Vistai; Radu Niculescu; Cristina Tarniceriu; Delia Dima; Cristina Truica; Margit Serban; Ciprian Tomuleasa; Daniel Coriu
Journal:  Ann Transl Med       Date:  2021-07

2.  F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China.

Authors:  Jie Sun; Zekun Li; Kun Huang; Di Ai; Gang Li; Xingjuan Xie; Hao Gu; Guoqing Liu; Yingzi Zhen; Zhenping Chen; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2022-06-08

3.  First report of inherited protein S deficiency caused by paternal PROS1 mosaicism.

Authors:  Satomi Nagaya; Keiko Maruyama; Atsushi Watanabe; Makiko Meguro-Horike; Yuta Imai; Yuki Hiroshima; Shin-Ichi Horike; Koichi Kokame; Eriko Morishita
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

4.  Case report: A novel case of parental mosaicism in SMC1A gene causes inherited Cornelia de Lange syndrome.

Authors:  Marta Gil-Salvador; Ana Latorre-Pellicer; Cristina Lucia-Campos; María Arnedo; María Teresa Darnaude; Aránzazu Díaz de Bustamante; Rebeca Villares; Carmen Palma Milla; Beatriz Puisac; Antonio Musio; Feliciano J Ramos; Juan Pié
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

5.  Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations.

Authors:  Limin Huang; Liyan Li; Sheng Lin; Juanjuan Chen; Kun Li; Dongmei Fan; Wangjie Jin; Yihong Li; Xu Yang; Yufeng Xiong; Fenxia Li; Xuexi Yang; Ming Li; Qiang Li
Journal:  Mol Genet Genomic Med       Date:  2020-09-01       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.